Key Highlights
- Cue Biopharma reported positive Phase 2 CUE-221 data in chronic spontaneous urticaria.
- The trial met all primary endpoints and its key secondary endpoint at the 4 mg/kg dose.
- The 4 mg/kg dose showed 12-week durable off-treatment benefit.
- A post-hoc analysis showed an edge over omalizumab at Week 28.
Cue Biopharma, Inc. (NASDAQ: CUE) reported positive Phase 2 CUE-221 data in chronic spontaneous urticaria, meeting all primary endpoints and its key secondary endpoint at 4 mg/kg with significant improvements over placebo and a favorable safety profile.
Company Overview
Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of engineered Biologics designed to selectively engage and modulate T cells to treat various diseases, including autoimmune disorders and cancer. The company's proprietary Immuno-STAT platform is designed to directly and selectively engage and modulate specific T cell populations without broadly suppressing the immune system, an approach intended to improve upon the safety and efficacy limitations of earlier-generation immunomodulatory therapies.
The company has applied its Immuno-STAT platform across multiple therapeutic areas, including autoimmune and inflammatory conditions such as chronic spontaneous urticaria, alongside earlier oncology-focused programs, reflecting a broader strategy of leveraging the same core technology platform across different disease areas where selective T cell modulation may provide therapeutic benefit.
What Happened
The 4 mg/kg dose demonstrated 12-week durable off-treatment benefit and a post-hoc edge over omalizumab at Week 28, supporting Phase 2b/3 CSU trials and food allergy development.
Market Reaction
The disclosed information does not include stock price or trading data for Cue Biopharma following the CUE-221 data release.
Outlook
The planned Phase 2b/3 CSU trials, along with continued food allergy development building on the CUE-221 platform, represent the next major disclosed milestones for Cue Biopharma's Immuno-STAT-based pipeline.






Please wait processing your request...